But diabetes isnt the only concern
My team and I set out to test whether GLP-1 drugs medications like semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound), originally developed for diabetes and then approved for obesity could do what no existing addiction treatment does: curb craving itself
Joseph Schacht, PhD, associate professor of psychiatry, talked about GLP-1s psychological effects and potential as an addiction treatment
Finally, one trial in 239 participants already suffering from chemotherapy-induced peripheral neuropathy reported a reduction in the severity of neuropathic symptoms with ALCAR (3 g/day for eight weeks) compared to placebo (93)
Association of COVID-19 with new-onset Alzheimers disease
Notably, many human studies of GLP-1RAs exclude people with a history of major depression, which could be why this side effect has gone under the radar